TFPI Monoklonaler Antikörper

TFPI Monoklonal Antikörper für WB,ELISA

Wirt / Isotyp

Maus / IgG2a

Getestete Reaktivität

human

Anwendung

WB,ELISA

Konjugation

Unkonjugiert

Publikationen

1

CloneNo.

1B12F11

Kat-Nr. : 66842-1-Ig

Synonyme

EPI, Extrinsic pathway inhibitor, LACI, TFI, TFPI, TFPI1

---

Galerie der Validierungsdaten

• 

  WB analysis of human placenta using 66842-1-Ig

  human placenta tissue were subjected to SDS PAGE followed by western blot with 66842-1-Ig (TFPI antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HepG2 using 66842-1-Ig

  HepG2 cells were subjected to SDS PAGE followed by western blot with 66842-1-Ig (TFPI antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: humanes Plazenta-Gewebe, HepG2-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:3000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• WB: See 1 publications below

Produktinformation

66842-1-Ig bindet in WB,ELISA TFPI und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Maus / IgG2a
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: TFPI fusion protein Ag14980
• Vollständiger Name: tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)
• Berechnetes Molekulargewicht: 251aa,29 kDa; 304aa,35 kDa
• Beobachtetes Molekulargewicht: 35-38 kDa
• GenBank-Zugangsnummer: BC015514
• Gene symbol: TFPI
• Gene ID (NCBI): 7035
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Tissue factor pathway inhibitor (TFPI) is a critical anticoagulant protein present in endothelium and platelets. TFPI is produced as two major isoforms in humans, TFPIa and TFPIb that result from alternative splicing. The TFPIb isoform localizes to the endothelium surface where it is a potent inhibitor of tissue factor-factor VIIa complexes that initiate blood coagulation. The TFPIa isoform is present in platelets. TFPI is a Kunitz-type serine protease inhibitor that exerts anticoagulant activity by blocking early procoagulant stimulia. TFPI can enhance anti-thrombotic treatment in sepsis, inflammatory diseases, and cardiovascular diseases.

Publikationen

Species	Application	Title
human	WB	Cell Death Dis; Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.; Authors - Ting Li